Learn how clinicians tailor antidepressants by diagnosis, symptoms, adverse effects, and next-step strategies for treatment-resistant depression.
|Articles|February 25, 2013
Mini-quiz: Major Depressive Disorder
Major depression is a common chronic illness within the general US population. What is the approximate prevalence for MDD in the US population?
Advertisement
Major depression is a common chronic illness within the general US population. How common? Take the quiz, learn more.
For the answer,
Answer:c
Major depression is a common chronic illness within the general US population, with a prevalence of approximately 5% to 10%.
For more on this topic, please see
Advertisement
Related to this article
Explore major depression subtypes—from melancholic to inflammatory—and how they shape symptoms, biology, and treatment choices for better outcomes.
The evidence points toward an overall protective effect in adult cohorts and no increase in completed suicide in younger populations.
This study compared the efficacy and tolerability of the 5 second-generation antipsychotics that are currently FDA approved as adjunctive treatments for adults with MDD.
Ketamine or esketamine during C-section anesthesia lowers early postpartum depression symptom scores in trials, hinting at a new prevention approach under study.
Real-world data show TRD costs spike during resistant episodes; Compass’ psilocybin COMP360 delivers durable symptom relief through 26 weeks, potentially easing resource strain.
TRD often mislabels depression; learn why MDD heterogeneity demands tailored treatments and when “difficult-to-treat” fits better.
First US TRD Awareness Day spotlights treatment-resistant depression, urging earlier recognition, stigma-breaking support, and renewed hope for patients and caregivers.
Advertisement
Advertisement
Trending on Psychiatric Times
1
Comparison of Atypical Antipsychotics as Adjunctive Treatments for Major Depressive Disorder
2
Improving but Not Feeling It: Anticipatory Anhedonia and Cognition
3
ADHD Medications for Managing Menopausal Brain Fog: Improvements in Subjective Executive Function
4
Positive Topline Results From Phase 2 Trial of RAP-219 for the Treatment of Bipolar Mania
5